

GLAXOSMITHKLINE PLC

Form 6-K

July 02, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending July 2012

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 29 June 2012, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.54 per Ordinary Share, and notional ADSs at a price of \$45.37 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2012 to 30 June 2012:

Non Executive Director	Ordinary Shares	American Depositary Shares (ADSs)
Sir Christopher Gent	2,321.183	
Professor Sir Roy Anderson	580.296	
Dr Stephanie Burns		454.703
Stacey Cartwright	322.387	
Lawrence Culp		909.406
Sir Crispin Davis	2,149.243	
Judy Lewent		227.352
Sir Deryck Maughan		909.406
Dr Daniel Podolsky		876.927
Tom de Swaan	795.220	
Sir Robert Wilson	580.296	

The Company and the Non-Executive Directors were informed of these allocations on 2 July 2012.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Company Secretary  
2 July 2012

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: July 2, 2012

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc